The Scientific Basis of Body Surface Area–Based Dosing
- 1 April 2014
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 95 (4) , 359-361
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agentsBritish Journal of Cancer, 2012
- Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice GuidelineJournal of Clinical Oncology, 2012
- A Universal Formula Based on Cystatin C to Perform Individual Dosing of Carboplatin in Normal Weight, Underweight, and Obese PatientsClinical Cancer Research, 2009
- Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patientsCancer Chemotherapy and Pharmacology, 2005
- Prospective Evaluation of Body Surface Area as a Determinant of Paclitaxel Pharmacokinetics and Pharmacodynamics in Women with Solid TumorsClinical Cancer Research, 2004
- Population pharmacokinetics of cisplatin in adult cancer patientsCancer Chemotherapy and Pharmacology, 2004
- Randomized Cross-Over Evaluation of Body-Surface Area–Based Dosing Versus Flat-Fixed Dosing of PaclitaxelJournal of Clinical Oncology, 2003
- Body surface area estimation in children using weight alone: application in paediatric oncologyBritish Journal of Cancer, 2001
- Dose and time dependencies of 5-fluorouracil pharmacokineticsClinical Pharmacology & Therapeutics, 2000
- Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.Journal of Clinical Oncology, 1996